Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2008064130) SPECTROSCOPIE D'UN TISSU PAR DES IR MÉDIANS
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED
1. A method of accurately measuring body cholesterol levels without inaccuracies related to recent diet, the method comprising:
irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue;
measuring resulting mid-infrared radiation;
comparing the measured radiation to stored reference data to obtain correlation information; and
using the correlation information to determine body lipid levels without inaccuracies related to recent diet.
2. The method of Claim 1, wherein measuring resulting mid-infrared radiation comprises measuring reflected mid-infrared radiation.
3. The method of Claim 1, wherein measuring resulting mid-infrared radiation comprises measuring transmitted mid-infrared radiation.
4. The method of Claim 1, wherein irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue comprises irradiating skin tissue with mid-infrared radiation to excite all cholesterol molecules within superficial layers of the tissue.
5. The method of Claim 1, wherein irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue comprises irradiating skin tissue with mid-infrared radiation to excite esterified cholesterol molecules within superficial layers of the tissue.
6. The method of Claim 1, wherein irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue comprises irradiating skin tissue with mid-infrared radiation to excite free cholesterol molecules within superficial layers of the tissue.
7. The method of Claim 1, wherein irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue comprises irradiating skin tissue with mid-infrared radiation to excite free fatty acids within superficial layers of the tissue.

8. The method of Claim 1 , wherein irradiating skin tissue with mid-infrared radiation to excite lipid molecules within superficial layers of the tissue comprises irradiating skin tissue with mid-infrared radiation to excite ceramides within superficial layers of the tissue.
9. The method of Claim 1, further comprising using a lipid level in a body to assess a disease.
10. The method of Claim 9, wherein using the lipid level to assess a disease comprises using body cholesterol to diagnose psoriasis.
1 1. The method of Claim 9, wherein using the lipid level to assess a disease comprises using esterified cholesterol to diagnose psoriasis.
12. The method of Claim 9, wherein using the lipid level to assess a disease comprises using a ceramide to diagnose psoriasis.
13. The method of Claim 9, wherein using the lipid level to assess a disease comprises using a free fatty acid level to diagnose psoriasis.
14. The method of Claim 9, wherein using the lipid to assess a disease comprises using body cholesterol to assess risk of cardiovascular disease.
15. A method of determining a living body's long-term deposition pattern of a compound, the method comprising:
placing skin of a living body against a receptor;
directing mid-infrared electromagnetic radiation onto the skin of the living body;
quantifying the electromagnetic radiation that is reflected from the skin to obtain a reflected amount;
using a calibration equation to calculate the concentration of a compound from the reflected amount; and
using the concentration of the compound to evaluate risk of a clinical condition.
16. The method of Claim 15, wherein using a calibration equation to calculate the concentration of a compound from the reflected amount comprises using a least-squares best fit statistical comparison.

17. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using the concentration of the compound to evaluate risk of cardiovascular disease.
18. The method of Claim 15, wherein using a calibration equation to calculate the concentration of a compound from the reflected amount comprises using a calibration equation to calculate the concentration of a lipid from the reflected amount
19. The method of Claim 18, wherein using a calibration equation to calculate the concentration of a lipid from the reflected amount comprises using a calibration equation to calculate the concentration of cholesterol from the reflected amount.
20. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using an algorithm that indicates correlation between amount of the compound and presence of a medical condition.
21. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using an algorithm that indicates correlation between amount of the compound and severity of a medical condition.
22. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using an algorithm that indicates correlation between amount of the compound and risk of a developing a medical condition.
23. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using an algorithm that indicates correlation between amount of the compound and a prediction of success of a treatment for a medical condition.
24. The method of Claim 15, wherein using the concentration of the compound to evaluate risk of a clinical condition comprises using an algorithm that indicates correlation between amount of the compound and a documentation of success of a treatment for a medical condition.
25. A method of testing for a type of cholesterol to diagnose a clinical condition, the method comprising:
preparing tissue;
placing a probe in proximity to tissue;

irradiating tissue with infrared radiation, thereby exciting molecules of a species in the tissue;
collecting resulting information from those molecules to determine a concentration of molecules of that species within the tissue; and
correlating the concentration to a clinical condition.
26. The method of Claim 25, wherein preparing comprises scraping.
27. The method of Claim 25, wherein preparing comprises cleaning.
28. The method of Claim 25, wherein placing a probe in proximity to tissue comprises contacting the probe to the tissue;
29. The method of Claim 25, wherein preparing tissue comprises preparing skin tissue and wherein irradiating tissue comprises irradiating the skin tissue.
30. The method of Claim 25, wherein irradiating tissue with infrared radiation comprises irradiating tissue with mid-infrared radiation.
31. The method of Claim 25, wherein correlating the concentration to a clinical condition comprises correlating the concentration to a propensity for a clinical condition.
32. The method of Claim 25, wherein the tissue is skin, further comprising all of the same steps performed at least a second time on a second tissue portion located deeper in a subject's skin.
33. The method of Claim 25, wherein the tissue is skin, further comprising all of the same steps performed at least a second time on a second tissue portion located on the same skin level.
34. The method of Claim 33, wherein the steps are performed one time on skin affected by a dermatological condition and another time on skin unaffected by the dermatological condition.
35. A spectroscopic method of measuring one or more cholesterol species in tissue, the method comprising:
selecting one or more mid-infrared radiation wavelengths to provide information about the one or more cholesterol species;
irradiating tissue with the one or more mid-infrared wavelengths;
measuring non-absorbed radiation;

calculating, using the measured radiation to determine quantities of the one ore more cholesterol species in the tissue; and
storing the result of the calculation in a computer-readable medium.
36. The method of Claim 35, wherein selecting one or more mid-infrared radiation wavelengths to provide information about the one or more cholesterol species comprises selecting at least two wavelengths to identify at least two cholesterol species.
37. The method of Claim 35, wherein selecting one or more mid-infrared radiation wavelengths to provide information about the one or more cholesterol species comprises selecting wavelengths to identify non-free cholesterol.
38. The method of Claim 35, wherein calculating comprises comparing the quantity of one species of cholesterol to the quantity of another species of cholesterol.
39. The method of Claim 38, wherein calculating comprises taking a ratio between data from one wavelength to the data from another wavelength.
40. The method of Claim 35, further comprising quantifying free, esterified, and total cholesterol by taking measurements of only two of the three cholesterol species.
41. A method of testing for dermatological disease, the method comprising:
providing a source of infrared radiation;
providing a dermatological sample;
directing the infrared radiation to illuminate the dermatological sample;
detecting radiation reflected from the dermatological sample; and
using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample.
42. The method of Claim 41, wherein providing a source of infrared radiation comprises providing a source of mid-infrared radiation.
43. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of total cholesterol.
44. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of free cholesterol.

45. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of esterified cholesterol.
46. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of free fatty acids.
47. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of ceramides.
48. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease comprises calculating concentration of an analyte related to psoriasis.
49. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample comprises diagnosing a sample.
50. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample comprises grading the severity of a sample.
51. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample comprises predicting further outbreak of the disease.
52. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample comprises predicting success of a treatment of the disease.
53. The method of Claim 41, wherein using the detected radiation to calculate concentration of an analyte related to a dermatological disease to determine a disease status of the sample comprises quantifying the success of treatments.
54. An apparatus for determining how effectively skin absorbs medication, the apparatus comprising:
a mid-infrared radiation source;

a skin holder;
a radiation detector configured to detect and transmit radiation information in response to mid-infrared radiation impinging on the detector;
a radiation path from the radiation source to the skin to the radiation detector; a processor configured to receive data from the radiation detector and determine, from the data, quantities of medication in the skin.
55. The method of Claim 54, wherein the processor is further configured to determine quantitative information regarding esterified tissue cholesterol.
56. A method of diagnosing a systemic condition, the method comprising:
irradiating a dermatological sample with mid-infrared radiation;
measuring non-absorbed radiation;
calculating, from the non-absorbed radiation, how much radiation was absorbed to determine a quantity of an absorbing substance in the dermatological sample; and
correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition.
57. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of hydration in the dermatological sample to diagnose body hydration or intravascular volume.
58. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of glycosylated products in the dermatological sample to determine a systemic blood sugar level trend.
59. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises diagnosing inflammation and/or infection related to a wound.
60. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of a glycosylated species in the dermatological sample to diagnose and/or evaluate treatment prognosis for diabetic disease.
61. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of cholesterol and/or phospholipids in the dermatological sample to diagnose diabetes.
62. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of bacterial species in the dermatological sample to assess their effects on the progress of wound healing.
63. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of bacterial species in the dermatological sample to determine the permeability of the dermatalogical sample to topically applied subststances.
64. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the amount of bacterial species in the dermatological sample to determine the susceptibility of the dermatalogical sample to pharmacological compounds.
65. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises assessing cancerous or pre-cancerous tissue.
66. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises assessing aging skin characteristics.
67. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the accumulated products of metabolism errors in the dermatological sample to diagnose a systemic condition.
68. The method of Claim 67, wherein correlating the accumulated products of metabolism errors in the dermatological sample comprises quantifying PKU.

69. The method of Claim 67, wherein correlating the accumulated products of metabolism errors in the dermatological sample comprises quantifying bilirubin.
70. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises correlating the accumulated products of toxic exposure in the dermatological sample to assess exposure of the dermatological sample.
71. The method of Claim 70, wherein correlating the accumulated products of toxic exposure in the dermatological sample comprises quantifying phenols.
72. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample to diagnose a systemic condition comprises quantifying the accumulated products of illicit drug use in the dermatological sample.
73. The method of Claim 72, wherein quantifying the accumulated products of illicit drug use comprises quantifying THC.
74. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample comprises correlating the amount of the absorbing substance in hair.
75. The method of Claim 56, wherein correlating the amount of the absorbing substance in the dermatological sample comprises correlating the amount of the absorbing substance in nails.